natgillin/translations-raw huggingface dataset:
Alternatively, some or all of the active material and some or all of one or more excipients may be added to the fluid before mixing with the remaining dry material. 
Postupak sukladno patentnom zahtjevu 16, pri čemu se neki 1li svi od aktivnih materijala 1 neki ili svi od jednog ili više ekscipijensa dodaju u tekućinu prije miješanja s preostalim suhim materijalom.
FIG. 10 provides a diagram showing the connection of the receiver, used in the present invention, to a device for generating an external acoustic signal. 
Slika 10 je dijagram koji prikazuje spoj prijemnika, koji se koristi u opisanom izumu, i uređaja za generiranje vanjskog akustičkog signala; te
Specifically, the invention is directed to compounds of formula (I): and salts thereof. 
HR P20171450 T1 PATENTNI ZAHTJEVI Kombinacija, naznačena time što sadrži spoj formule (I):
A composition comprising nanoparticles that comprise rapamycin and a carrier protein, for use in a method of treating cancer in a human, wherein the amount of rapamycin is in the range of 25 mg/m2 to 100 mg/m2, or wherein the amount of rapamycin is in the range of 50 mg to 175 mg. 
HR P20181159 T1 PATENTNI ZAHTJEVI Pripravak koji sadrži nanočestice koje sadrže rapamicin i protein nosač, za upotrebu u postupku liječenja raka kod čovjeka, naznačen time što je količina rapamicina u rasponu od 25 mg/m* do 100 mg/m', ili pri čemu je količina rapamicina u rasponu od 50 mg do 175 mg.
A combination comprising a therapeutically effective amount of a compound of the invention in free or salt form and, where possible, in pharmaceutically acceptable acid addition salt form and a second drug substance, said second drug substance being, e.g., for use in any of the particular indications set forth hereinabove. 
(4) kombinaciju koja obuhvaća terapeutski učinkovitu količinu spoja formule (1) ili (Ia) u slobodnom obliku ili u obliku soli 1, gdje je to moguće, u obliku farmaceutski prihvatljive kiselnske adicijske soli 1 druge ljekovite tvari, pri čemu spomenuta druga ljekovita tvar može biti, npr. za upotrebu kod bilo koje od gore navedenih posebnih indikacija.
Cy is phenyl substituted with CN and optionally substituted with one or two additional groups independently selected from —Cl, —F and C1-3alkyl; is —CH3; and 
Cy je fenil koji je supstituiran sa CN i opcijski supstituiran s jednom ili dvije dodatne skupine neovisno odabrane od sljedećih: -C1, -F 1 C;.2-alkil;
if the respective audio block is the first audio block in the frame: 
(a) ako je odgovarajući audio blok prvi audio blok u okviru:
Physical examination, investigations to exclude diabetes mellitus (and possibly HIV infection), and mycological investigation are essential and, if possible, should be performed when the patient has symptoms but has had no treatment (see Denning D.W., BMJ 1995;310:1241-1244). 
Tjelesni pregled, ispitivanja da se isključi šećerna bolest (i po mogućnosti HIV infekcija), te mikološka ispitivanja su nužni te, ukoliko je moguće, trebaju biti provedeni kada pacijent ima simptome ali još nije primio nikakav tretman (vidi Denning D.W., BMJ 1995.; 310:1241-1244).
The reaction of step (j) is carried out at a temperature in the range of from 60 to 90° C., conveniently 60 to 80° C., more conveniently in the range of from 70 to 75° C. 
Postupak prema zahtjevu 6, naznačen time, da R' je benzil, a u koraku (i) se benzilna skupina odstranjuje in situ pomoću reakcije sa trifluorooctenom kiselinom na temperaturi u rasponu od 60 do 80% C. 8.
Detection wavelength: 256 nm 
256 nm Dužina trajanja otprilike:
A cocktail of polypeptides comprising at least two different polypeptides, wherein the at least two different polypeptides comprise a cocktail of polypeptides selected from the group consisting of: a cocktail of: a polypeptide comprising the sequence of SEQ. 
Koktel polipeptida koji sadrži barem dva različita polipeptida, gdje najmanje dva različita polipeptida sadrže koktel polipeptida odabran iz grupe koja se sastoji od: i) - koktela od: polipeptida koji sadrži sekvencu sa SEQ.
Liquid compositions are usually in dosage unit ranges. 
Tekuće smjese su obično u opsezima jedinične doze.
is a methine group optionally substituted by a hydroxyl group or a lower alkyl group, Q3 is a single bond, and R1d and R1e are independently a hydrogen atom or a lower alkyl group; 
je metin skupina po izboru supstituirana hidroksil skupinom ili nižom alkilnom skupinom, Q3 je jednostruka veza, i R1d i R1e su nezavisno atom vodika ili niža alkilna skupina;
wherein the amount of free palmitic acid is at least 40%, preferably at least 45%, more preferably at least 50%, still more preferably at least 55%, even more preferably at least 60%, further more preferably at least 65%, still further more preferably at least 70%, even further more preferably at least 75%, still even further more preferably at least 80%, even still further more preferably at least 85%, and most preferably at least 90% by weight of the total lipids. 
HR P20180872 T1 naznačeno time da je iznos slobodne palmitinske kiseline barem 40%, poželjno barem 45%, poželjnije barem 50%, još poželjnije barem 55%, čak poželjnije barem 60%, znatno poželjnije barem 65%, znatno još poželjnije barem 70%, čak znatno poželjnije barem 75%, čak znatno još poželjnije barem 80%, još znatnije poželjnije barem 85%, i najpoželjnije 90% težine ukupnih lipida.
a conduit (21) for inflow of said slurry (3) into said chamber (20); 
(c) cjevovod (21) za protočno ulaženje navedenog mulja (3) u navedenu komoru (20);
Therefore, fructose can exist in its a-fructopyranose, B-fructopyranose, a-fructofuranose or, B-fructofuranose or open chain forms as shown in Fig. 6. 
Prema tome, fruktoza može postojati u svojem a-fruktopiranoznom, B- fruktopiranoznom, a-fruktofuranoznom ili B-fruktofuranoznom ili otvorenom lačanom obliku, kako je prikazano na slici 6.
The method of claim 14, wherein in step (a) said solid support is located within said-external column. 
Postupak sukladan bilo kojem od zahtjeva 14 ili 15, naznačen time, da spomenuta kruta potpora se nalazi unutar spomenute kolone.
In another embodiment of the invention, said transformed microalgae further comprise a nucleotide sequence operably linked to a promoter that drives expression in said microalgae, wherein said nucleotide sequence encodes an N-acetylglucosaminyltransferase I enzyme that is expressed in the transformed microalgae. 
Metoda u skladu sa bilo kojim od patentnih zahtjeva 1 do 3, gdje navedena transformirana mikroalga dalje sadrži nukleotidnu sekvencu operativno vezanu za pokretač koji pokreće ekspresiju u navedenoj mikroalgi, gdje navedena nukleotidna sekvenca kodira N-acetilglukozaminiltransferaza I enzim (Gnt I) koji je eksprimiran u transformiranoj mikroalgi.
Atomizer according to claim 30, wherein the counter is resettable when the container is changed, and wherein the resetting is locked in the assembled state of the atomizer. 
Raspršivač prema zahtjevu 10, naznačen time, da se brojčana vrijednost može ponovno namjestiti ručno ili automatski kada se zamjenjuje spremnik (3), posebno dok je ponovno namještanje zaključano u sklopljenom stanju raspršivača (1).
Figure 3: Yeast expression plasmid Map Figure 4: Expression Plasmid for Eu XI A protein having at least 70% identity, preferably 80% identity, most preferably 90 % identity, most highly preferably 95 % identity to SEQ ID NO. 
Stanica kvasca koja daje informaciju o proteinu koji sadrži aminokiselinsku sekvencu koji ima najmanje 80% identičnosti, poželjno 90% identiteta, najpoželjnije 95% identičnosti sa SEQ ID br. 2 i koja ima ksilozno-izomeraznu aktivnost u stanici kvasca.
The anti-IL-5 antibody for the use as claimed in claim 1, wherein said composition comprising the antibody is to be administered intramuscularly. 
Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što navedeni pripravak koji sadrži protutijelo treba primijeniti intramuskularno.
The use as claimed in claim 12, wherein said composition is administered twice daily in a dose of from 5 to 10 milligrams of aminopyridine. 
Upotreba prema zahtjevu 12, naznačena time da je spomenuti sastav primijenjen dvaput dnevno u dozi od 5 do 10 miligrama aminopiridina.
Use of a compound as claimed in any of the preceding claims in the manufacture of a medicament for the treatment of pulmonary hypertension, erectile dysfunction, systemic hypertension, congestive heart failure (CHF), migraine, hypertension, disorders of the gastrointestinal tract, restenosis, asthma, obstructive airway disease, prostatic hyperplasia, priapism, inflammatory pain, neuropathic pain, cancer pain, acute pain, chronic pain, irritable bowel syndrome, hypertonic lower esophageal sphincter, motility disorders, benign prostatic hyperplasia, depression, anxiety, attention deficit hyperactivity disorder, obesity, sleeping disorder, Alzheimer's disease, Parkinson's disease, carcinoid tumours, teratocarcinoma, hyperprolactinemia, acromegaly, CNS disorder or any other disease state that is alleviated by treatment with a 5-HT2B antagonist. 
Upotreba spoja kao što je zahtijevano prema bilo kojem od prethodnih zahtjeva, naznačena time da je za upotrebu u proizvodnji pripravaka za liječenje plućne hipertenzije, erektilne disfunkcije, sistemske hipertenzije, kongestivnog zatajivanja srca (CHF), migrene, hipertenzije, bolesti gastrointestinalnog trakta, restenoze, astme, obstruktivne bolesti dišnih puteva, hiperplazije prostate, prijapizma, upalne boli, neuropatske boli, karcinomske boli, akutne boli, kronične boli, sindroma razdražljivosti crijeva, hipertoničnog donjeg sfinktera jednjaka, motoričkih poremećaja, benigne hiperplazije prostate, depresije, anksioznosti, poremećaja hiperaktivnosti i deficita pažnje, pretilosti, poremećaja spavanja, Alzheimerove bolesti, Parkinsonove bolesti, karcinoidnih tumora, teratokarcinoma, hiperprolaktinemije, akromegalije, CNS bolesti ili bilo kojeg drugog bolesnog stanja koje je ublaženo liječenjem 5- HT» antagonistom.
Process according to one of claims 1 to 4, wherein said slurry of step a) has a solids content of greater than 4 wt.-%, preferably from 5 wt.-% to about 20 wt.-%, based on the weight of the slurry. 
Postupak prema jednom od zahtjeva 1 do 3, naznačen time da navedena suspenzija iz koraka a) ima sadržaj čvrstih tvari od više od 4 tež-%, poželjno od 5 tež-% do oko 20 tež-%, bazirano na težini suspenzije.
A process according to claim 5, wherein a laser is used which emits laser radiation at a wavelength which is absorbed by the porous layer for heating of it, so that the porous material in the area of the impinging laser radiation is vaporized for formation of the contact area. 
Postupak u skladu s najmanje jednim od prethodnih patentnih zahtjeva, naznačen time što se upotrebljava laser (21) koji emitira lasersko zračenje valne duljine koju apsorbira sinterirani, porozni sloj (12) kako bi se zagrijalo navedeni sloj na takav način da porozni materijal u području izloženom laserskom zračenju ispari kako bi se dobilo kontaktno područje (20).
The method of claim 1, wherein the initial density of said mammalian cells is at least 2x105 cells/mL. 
Postupak prema Zahtjevu 1, naznačen time, što je inicijalna gustoća spomenutih stanica sisavaca najmanje 2x10* stanica/mL,
The transdermal delivery device of items 1 or 3, wherein the opioid antagonist is in the form of stable crystalline particles. 
Sredstvo za transdermalno davanje prema zahtjevu 1, naznačeno time da je opioidni antagonist u obliku stabilnih kristalnih čestica.
A composition according to any preceding claim comprising an antimicrobial agent, an anti-fungal agent, an insecticidal agent, an anti-inflammatory agent or an anaesthetic. 
Sastav temeljem bilo kojeg od prethodnih zahtjeva koji sadrži antimikrobni agens, protufungalni agens, insekticidni agens, protuupalni agens, ili anestetik.
In particular embodiments of the compounds of formula (I), R4 is present at one of the ring atoms, and is selected from the group consisting of halogen, 
Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, gdje R* je prisutan na jednom od atoma prstena, i izabran je iz grupe koja se sastoji od
a cumulative total amount of methionine per unit volume greater than approximately 2.0 mM; 
(iv) kumulativna ukupna količina metionina po jedinici volumena veća od približno 2,0 mM;
delumping an extragranular lubricant using a screen or mill and blending with granules from the step (5); 
uklanjanja grudica iz ekstragranularnog lubrikanta upotrebom pogodnog sita/mlina i miješanje sa granulama iz koraka (4);
Appropriate carrier materials of this type for a particular base TPE and for use in pharmaceutical applications are well known in the polymers art and are available from numerous suppliers e.g. PolyColour Plastics Ltd., Telford, Shropshire GB. 
Prikladni materijali nosioci ove vrste za posebne osnovne TPE i za upotrebu u farmaceutskim primjenama su dobro poznati u struci koja se bavi polimerima i raspoloživi su od brojnih dobavljača, na primjer, PolyColour Ltd., Telford, Shropshire GB.
The composition of claim 10 wherein the ionic precipitating agent is ferric subsulphate present in the composition as Monsel's solution which Monsel's solution includes from 15% to 25% w/v iron (III) ions. 
Pripravak u skladu s patentnim zahtjevom 10, naznačen time, da je ionsko sredstvo za taloženje ferenski subsulfat prisutan u pripravku kao Monselova otopina, a navedena Monselova otopina sadržava od 15 % do 25 % težinskih udjela željeznih (III) iona.
A compound according to any of claims 1 to 5 for use in the treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što je namijenjen upotrebi u liječenju prekanceroznih lezija, displazija, metaplazija i tumorskih bolesti, što može uključivati zloćudne novotvorine i metastaze.
The combination for use according to any one of claims 3 to 5, wherein the complication of diabetes mellitus is diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, cerebrovascular disorder, ischemic cardiac disease, or peripheral arterial disease. 
Kombinacija za uporabu prema bilo kojem zahtjevu od 6 do 11, naznačena time da komplikacija dijabetes melitusa je dijabetička retinopatija, dijabetička nefropatija, dijabetička neuropatija, cerebrovaskularni poremećaj, ishemijska bolest srca, ili bolest perifernih arterija.
Preparation of the Hydrogen sulfate salt of Compound 1 
Datum podnošenja europske prijave patenta:
The pharmaceutical composition according to claim 25, additionally comprising other active ingredients. 
Farmaceutski pripravak prema zahtjevu 25, naznačen time da dodatno sadrži druge aktivne sastojke.
A herbicide containing the benzoylpyrazole compound or its salt as defined in claim 1 as an active ingredient. 
Herbicid koji sadrži spoj benzoilpirazola ili njegovu sol kako je definirano u patentnom zahtjevu 1, naznačen time, da je kao djelatni sastojak.
Its hydrochloride salt formulation is currently available under the trade name Effexor®, which is marketed as a racemic mixture, i.e. 
Njegova formulacija u obliku hidrokloridne soli trenutno je dostupna pod trgovačkim nazivom Effexor", što se prodaje kao racemičnu smjesu, tj.
Labels identify the number of the isolation. 
Broj objave europskog patenta:
A compound of formula (II), a salt, or a stereoisomer thereof, 
Spoj formule (II), sol, ili a njegov stereoizomer R?
A 5-D-fructose dehydrogenase for use in medicine. 
-D-fruktoza dehidrogenaza za uporabu u medicini.
The liquefied gas treatment method according to claim 1, wherein the compressor includes a plurality of compression cylinders, and the BOG generated in the cargo tank is compressed by a part of the plurality of compression cylinders and is supplied as fuel to the sub engine. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 4, naznačen time što otpareni plin poslan u izmjenjivač topline (21) je otpareni plin komprimiran prilikom prolaska kroz sve ili dio kompresijskih elemenata koje sadrži kompresor (13,13,13b).
Other examples of remote control, in the marine field, are given in U.S. Pat. 
Drugi primjeri daljinskog upravljača, u području pomorstva, su dani u patentima U.S. Patent Br.
The process of claim 1, wherein the first organic solvent is an aprotic solvent. 
Postupak prema patentnom zahtjevu 2, pri čemu je organsko otapalo korišteno u koraku ic, neprotonsko otapalo.
separating the A9-tetrahydrocannabinol from the resulting phase containing the A9-tetrahydrocannabinol; and 
separaciju trans-(-)-A9-tetrahidrokanabinola i trans-(+)-A9-tetrahidrokanabinola od alkoholno-kaustične faze; i
with an intermediate of formula R6—R1C(O)OH, using standard amine coupling conditions to yield a compound of Formula I, where: 
s intermedijerom s formulom R6-R1C(O)OH, koristeći standardne uvjete vezanja amina da se dobije spoj s formulom I, gdje:
an antisense oligomer comprising a nucleotide sequence of SEQ ID NO: 1 or 2; 
antisensni oligomer koji sadrži nukleotidnu sekvencu SEQ ID NO: 1 ili 2;
suspending avian embryonic stem (ES) cells obtained by dissociating embryo(s) of step a) in a basal culture medium supplemented with: 
suspendiranje ptičjih embrijskih matičnih (ES) stanica dobivenih disocijacijom embrija u koraku a) u bazalnom mediju kulture s dodatkom:
The process according to claim 11, wherein said microfiltration is carried out at a cutoff of about 0.45 µm, 0.2 µm, 0.1 µm. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time, da se rečena mikrofiltracija izvodi na dopustivoj granici od oko 0.45 um, 0.2 um, 0.1 um.
The system of, claim 5 wherein the mask compartment comprises an exhaust port. 
Uređaj CPAP (105) u skladu s patentnim zahtjevom 1, naznačen time što dodatno ima ispušni izlaz na odjeljku maske (116).
a fourth polynucleotide comprising or consisting of at least the sequence 5'-TGCACATCATG-3' (SEQ ID NO: 10) and a PCR blocking component, or comprising or consisting of at least the sequence 5'-GAATGATGCACATCATGGTGG-P-3' (SEQ ID NO: 11), and wherein P is phosphate, and 
SEKV.: 6), i u kojoj se P odnosi na fosfat, a A na dodatnu nepodudarnost, i četvrtog polinukleotida koji se sastoji od barem sekvence 5’-TGCACATCATG-3’ (ID BR. SEKV.: 10) i PCR blokirajuće komponente, ili se sastoji od barem sekvence 5’-GAATGATGCACATCATGGTGG-P-3’ (ID BR.
The long term storage stable non-aqueous liquid bendamustine-containing composition of any of the previous claims, wherein the antioxidant is selected from the group consisting of thioglycerol, monothioglycerol, lipoic acid, propyl gallate, methionine, cysteine, metabisulfites, sodium formaldehyde sulfoxylate, phenol-containing aromatic and aliphatic compounds and dihydrolipoic acid. 
Stabilan pri dugotrajnom skladištenju, nevodeni tekući pripravak s bendamustinom prema bilo kojem od prethodnih zahtjeva, naznačen time, da je antioksidans odabran 1z skupine koju čine tioglicerol, monotioglicerol, lipoinska kiselina, propil galat, metionin, cistein, metabisulfiti, natrijev formaldehid sulfoksilat, aromatski i alifatski spojevi s fenolom i dihidrolipoinska kiselina.
The blender container 106 also includes a base 110 . 
Posuda mješalice 106 također uključuje postolje 110.
The flexible wing (20) of claim 19, wherein at least one cable is made of a material selected from the group consisting of steel, wire rope, aramid fibers, liquid crystal polymer fibers, and ultra-high-molecular-weight polyethylene fibers. 
Fleksibilno krilo (20) prema Zahtjevu 19, gdje je najmanje jedan kabel izrađen od materijala odabranog iz grupe koja sadrži čelik, žičanu užad, vlakna aramida, vlakna tekućih kristalnih polimera 1 vlakna polietilena ultra visoke molekularne težine.
The compound according to claim 1, wherein X and Y represent oxygen. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da X predstavlja atom kisika, Y predstavlja atom kisika, a Z predstavlja CH.
The device according to claim 1, wherein the chassis comprises a number of rolling elements. 
Uređaj sukladno zahtjevu 1, gdje šasija sadrži određeni broj rotirajućih elemenata.
The invention generally concerns a sanding element, more particularly a laminated disc, which contains successive overlapping lamellas. 
Ovaj izum se općenito odnosi na element za brušenje, još posebnije na lamelirani disk koji se sastoji od elemenata koji se preklapaju i koji su postavljeni jedan iza drugoga.
Apelin analog according to claim 1, selected from the group consisting of: 
Analog apelina prema zahtjevu 1, odabran od skupine koja se sastoji od:
Anti-Alzheimer's disease active agent for use according to any one of claims 4-9, wherein said genetic variant is a poly-T deletion/insertion polymorphism having a poly-T length of between 20 and 50 contiguous base pairs at rs10524523. 
Postupak prema zahtjevu 16, naznačen time, da genetička varijanta od TOMM40-gena je polimorfizam s izbacivanjem/umetanjem rs10524523, koja ima poli-T između 20 1 50 zaraženih osnovnih parova.
Nicotinic acid (niacin, pyridine-3-carboxylic acid) is a water-soluble vitamin required by the human body for health, growth and reproduction; a part of the Vitamin B complex. 
Nikotinska kiselina (niacin, piridin-3-karboksilna kiselina) je u vodi topiv vitamin neophodan u ljudskom tijelu za zdravlje, rast i reprodukciju; dio Vitamin B kompleksa.
The method of claim 30 further comprising inserting at least one second recombinant nucleic acid molecule into the bacterial cell, said second recombinant nucleic acid molecule encoding a peptide or polypeptide capable of eliciting an immune response in a mammal. 
Postupak prema zahtjevu 28, naznačen time što obuhvaća umetanje (inserciju) najmanje jedne dodatne rekombinantne molekule nukleinske kiseline u bakterijsku stanicu, a ta dodatna rekombinantna molekula nukleinske kiseline kodira peptid ili polipetid koji ima sposobnost izazvati imuni odgovor kod sisavca.
wherein R1 is a group of a peptide residue optionally protected with one or more protecting groups; or a salt thereof. 
R' je peptidni ostatak opcijski zaštićen s jednom ili više zaštitnih skupina; ili njegova sol.
The residue was triturated with ethyl acetate and the resulting solid collected, washed with ethyl acetate, and dried to give the title compound (1.23 g), m.p. 
Ostatak se usitni s etilacetatom i preostala čvrsta supstanca se sakupi, ispere s etilacetatom i suši tako da se dobi ja naslovni spoj (1,23 g), t.t. 126-129".
The use of any one of claims 1 to 9, wherein the AAV vector comprises a replication defective AAV genome lacking functional Rep and Cap coding viral sequences. 
AAV vektor iz bilo kojeg od patentnih zahtjeva 1 do 5, pri čemu AAV vektor obuhvaća replikacijom nedostatan AAV genom bez funkcionalnih Rep i Cap kodirajućih virusnih sljedova.
A compound according to any one of claims 1-3, wherein p is selected from 0, 1, 2, 3, 4 and 5. 
Spoj prema zahtjevu 1, naznačen time da je spoj izabran iz skupine koju čine. [image] [image]
A crystal form of (6S)-5-methyltetrahydrofolate salt, wherein the crystal form is: 
Kristalni oblik C (6S)-5-metiltetrahidrofolatne kalcijeve soli gdje:
The process of claim 16, wherein the temperature profile during the curing step shows a plateau-like form and wherein said temperature is preferably at least about 72 °C and the curing time is preferably in the range of from about 15 minutes to about 2 hours. 
Postupak prema zahtjevu 16, naznačen time da temperaturni profil u toku koraka stvrdnjavanja pokazuje oblik platoa i gdje je navedena temperatura barem oko 72 "€ i gdje je vrijeme stvrdnjavanja poželjno u rasponu od oko 15 minuta do oko 2 sata.
The compound of Claim 1 wherein the group is selected from the group consisting of: or wherein the group 
Spoj prema patentnom zahtjevu 1 naznačen time što je grupa [image] izabrana iz grupe koju čine:
applying a first solution that optionally comprises poly (ethylene glycol) and glycine to a cation exchange chromatographic material and thereby equilibrating the material, 
- nanošenje prve otopine koja po potrebi obuhvaća poli(etilenglikol) 1 sorbitol za kationsku izmjenu kromatografskog materijala, te time uravnotežavanje materijala,